Why biopharma & life sciences must look at new digital capabilities
The global pharmaceutical and life sciences industries have always operated in a tightly controlled and regulated environment. However, COVID-19 has created a highly testing landscape and is making new demands on pharma companies. Access to prescribers has further diminished. Clinical trials and new product launches have been impacted. Patients and payers have new challenges and expectations. Commercial leaders will need to re-visit their strategies to adapt to the sudden, but significant and long-term shifts in the healthcare ecosystem. Are pharma CRM and digital platforms ready to respond to the new dynamics effectively? Which technologies will empower commercial and digital leaders to nurture value-based engagements with stakeholders? How can pharma companies achieve transformation in their outcomes through precision targeting, highly personalized messaging, and geo-specific strategies?
This white paper examines:
- The shifts taking place in the healthcare ecosystem across prescribers, patients, products, and payers
- New digital and customer engagement strategies for pharma companies
- The role of digital and contemporary technologies like AI/ML, advanced analytics, and IoT in transforming outcomes for pharma and life sciences
